Literature DB >> 10586002

Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors.

R Wappner1, S Cho, R A Kronmal, V Schuett, M R Seashore.   

Abstract

OBJECTIVE: The development of guidelines for phenylketonuria (PKU) management in the United Kingdom has resulted in much discussion in the community of parents and PKU clinics and parents have asked why the United States does not have such guidelines. The objective of this report is to discuss PKU management in the United States, the British guidelines on PKU management, and the feasibility, suitability, and mechanism of developing PKU management guidelines in the United States.
METHODS: Members of the American Academy of Pediatrics (AAP) Committee on Genetics (COG) reviewed the literature and conducted surveys of parents of children with PKU, young adults with PKU, and directors of PKU clinics in the United States. A meeting was held at the National Institute of Child Health and Human Development to review the AAP/COG efforts at reviewing the status of PKU management and guideline development in the United States.
RESULTS: The British guidelines are more stringent than the PKU management practices in many parts of the United States. Evidence exists that stricter management improves developmental outcome. The parents who responded to the surveys indicated willingness to comply with more stringent dietary management if that would improve outcome. They also identified problems that make such management difficult. The clinic directors supported the timeliness of the review. Some had begun a trend toward more stringent control of blood phenylalanine concentrations, at least in the first 4 years of life.
CONCLUSION: The AAP Committee on Genetics will complete its subject review of the management of PKU. Guidelines for care of PKU in the United States probably would look quite similar to the existing guidelines in other countries. The parents surveyed supported more stringent PKU management, but information from a broader distribution of parents would provide a more representative view. The status of the US health care system creates problems for improved PKU management in the United States that do not exist in the countries already following stricter guidelines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586002     DOI: 10.1542/peds.104.6.e68

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  19 in total

1.  Living with phenylketonuria: perspectives of patients and their families.

Authors:  C Bilginsoy; N Waitzman; C O Leonard; S L Ernst
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

3.  Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations.

Authors:  Y H Chien; S C Chiang; A Huang; J M Lin; Y N Chiu; S P Chou; S Y Chu; T R Wang; W L Hwu
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

4.  Breastfeeding infants with phenylketonuria in the United States and Canada.

Authors:  Sandra A Banta-Wright; Nancy Press; Kathleen A Knafl; Robert D Steiner; Gail M Houck
Journal:  Breastfeed Med       Date:  2013-12-18       Impact factor: 1.817

5.  Phenylalanine Monitoring via Aptamer-Field-Effect Transistor Sensors.

Authors:  Kevin M Cheung; Kyung-Ae Yang; Nako Nakatsuka; Chuanzhen Zhao; Mao Ye; Michael E Jung; Hongyan Yang; Paul S Weiss; Milan N Stojanović; Anne M Andrews
Journal:  ACS Sens       Date:  2019-11-01       Impact factor: 7.711

6.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

7.  Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria.

Authors:  F J Rohr; A W Munier; H L Levy
Journal:  J Inherit Metab Dis       Date:  2001-11       Impact factor: 4.982

Review 8.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10

9.  Dry storage of multiple reagent types within a paper microfluidic device for phenylalanine monitoring.

Authors:  Lael Wentland; Rachel Polaski; Elain Fu
Journal:  Anal Methods       Date:  2021-01-19       Impact factor: 2.896

10.  Cell encapsulation as a potential nondietary therapy for maternal phenylketonuria.

Authors:  Donna A Santillan; Mark K Santillan; Stephen K Hunter
Journal:  Am J Obstet Gynecol       Date:  2009-07-24       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.